Anti-Hu CD255 Purified Low Endotoxin

Anti-Hu CD255 Purified Low Endotoxin
Regulatory status
RUO
Antigen
CD255
Clone
CARL-1
Format
Purified Low Endotoxin
Reactivity
Human
Variant
0.1 mg
12-756-C100
In stock
130.00 USD
Variant
0.1 mg
11-261-C100
In stock
130.00 USD
Product details
Description
References
Isotype
Mouse IgG3 kappa
Specificity
The mouse monoclonal antibody CARL-1 recognizes an extracellular epitope of CD255 / TWEAK, a type II transmembrane protein of the TNF superfamily able to induce apoptosis weakly in many cell types.
Application details
Functional application: Neutralization.
Flow cytometry: Recommended dilution: 1-4 µg/ml
Reactivity
Human
Immunogen
human CD255-transfected 2PK-3 cells
Concentration
1 mg/ml
Preparation
Purified by protein-A affinity chromatography
Formulation
Low endotoxin azide free phosphate buffered saline (PBS) solution, 0.2 μm filter sterilized. Endotoxin level is less than 0.01 EU/μg of the protein, as determined by the LAL test.
Storage and handling
Store at 2-8°C. Do not freeze. Do not use after expiration date stamped on the label.
Exbio licence note
The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.
Other names
TNFSF12, APO3L, DR3LG, TWEAK, TNLG4A
Antigen description
CD255 / TWEAK (TNF-related weak inducer of apoptosis), a type II transmembrane protein expressed as membrane-bound and secreted form, can induce apoptosis in many tissues and cell lines through its receptor CD266 / TWEAK R. On the other hand, in endothelial cells this interaction can induce proliferation and promote angiogenesis including neovascularization of tumours. CD255 can act in a juxtacrine manner to initiate cellular responses, and induces secretion of pro-inflammatory cytokines. Besides CD266, CD255 may also bind to DR3.
Entrez Gene ID 8742
UniProt ID O43508

Product specific references:

Yoriki R, Akashi S, Sho M, Nomi T, Yamato I, Hotta K, Takayama T, Matsumoto S, Wakatsuki K, Migita K, Yagita H, Nakajima Y: Therapeutic potential of the TWEAK/Fn14 pathway in intractable gastrointestinal cancer. Exp Ther Med. 2011 Jan;2(1):103-108
PubMed
Nakayama M, Ishidoh K, Kojima Y, Harada N, Kominami E, Okumura K, Yagita H: Fibroblast growth factor-inducible 14 mediates multiple pathways of TWEAK-induced cell death. J Immunol. 2003 Jan 1;170(1):341-8.
PubMed
Hosokawa Y, Hosokawa I, Ozaki K, Nakae H, Matsuo T: Proinflammatory effects of tumour necrosis factor-like weak inducer of apoptosis (TWEAK) on human gingival fibroblasts. Clin Exp Immunol. 2006 Dec;146(3):540-9.
PubMed
Saitoh T, Nakayama M, Nakano H, Yagita H, Yamamoto N, Yamaoka S: TWEAK induces NF-kappaB2 p100 processing and long lasting NF-kappaB activation. J Biol Chem. 2003 Sep 19;278(38):36005-12.
PubMed
Brown SA, Ghosh A, Winkles JA: Full-length, membrane-anchored TWEAK can function as a juxtacrine signaling molecule and activate the NF-kappaB pathway. J Biol Chem. 2010 Jun 4;285(23):17432-41.
PubMed
Nakayama M, Kayagaki N, Yamaguchi N, Okumura K, Yagita H: Involvement of TWEAK in interferon gamma-stimulated monocyte cytotoxicity. J Exp Med. 2000 Nov 6;192(9):1373-80.
PubMed
Variant
0.1 mg
12-756-C100
In stock
130.00 USD
Variant
0.1 mg
11-261-C100
In stock
130.00 USD